HeadBlade introduces new head shaving model
NEW YORK — After three years in development, HeadBlade is introducing its most innovative design since the original HeadBlade Classic in 1999. Enter the HeadBlade ATX All Terrain Razor.
The new HeadBlade ATX All Terrain Razor is now available online and will hit retail stores in early 2013. The manufacturer’s suggested retail price for ATX is $15 at headblade.com; the manufacturer’s suggested retail price for HB4 Blade Refills is $11.97 at headblade.com.
It is a completely new design that will be compatible with HeadBlade’s most advanced blade offering yet: the HB4 Blade Cartridge.
The ATX All Terrain Razor utilizes HeadBlade’ s patented finger ring and car-like suspension, but the new design now has the blade suspended in the back by a spring action device, reducing any learning curve and virtually eliminating the chance of nicks or cuts, the company stated. This new configuration also allows the ATX All Terrain Razor to be used as a multipurpose shaver, suitable for the face, body and legs. The HB4 Cartridge features improved blade quality with new open back architecture and flow-through design that allows for easy rinsing.
What sets HeadBlade razors apart, the company stated, is the fact that the user is able to shave by feel (with the razor sitting closer to the head and the user being able to touch the head with fingers while shaving). Launched in 1999, the original HeadBlade was offered with generic twin blade refills. In 2005, the HeadBlade Sport Razor was introduced with HeadBlade’s first OEM blade offering: the HB3 triple blades. The addition of wheels provided a smoother shave and made the razor more intuitive for the first-time user (the HeadBlade is meant to be driven like a car). Since then, all models have had a similar design to ensure ease and comfort for the user.
New Softlips Marshmallow Ghost hits shelves just in time for Halloween
ORCHARD PARK, N.Y. — The Mentholatum Co.’s Softlips brand has announced the launch of a new Halloween-themed lip balm that is hitting retail stores in early September.
The new Softlips Marshmallow Ghost will be featured as part of a Halloween-themed two-pack that includes the Softlips Vanilla lip balm.
Softlips Marshmallow Ghost features the flavor and fragrance of fresh, fluffy marshmallows. To make this pack even more bewitching, Softlips Marshmallow Ghost also will be offered in a limited edition black stick — a Halloween-appropriate twist on Softlips’ traditional white stick.
Both Softlips Marshmallow Ghost and Softlips Vanilla are moisturizing lip protectants with SPF 20, making them ideal for the upcoming colder months.
Study: Consumers hear less about risks when Rx drugs switch to OTC status
WOONSOCKET, R.I. — Most advertisements for over-the-counter versions of drugs did contain significantly less information about the risks of the medication, compared with the ads for the drug prior to its transition to OTC status, according to new research sponsored by CVS Caremark.
The research, published in this week’s issue of the Journal of the American Medical Association, identified differences between consumer-directed advertisements for drugs when they are available by prescription only, compared with when they transition to OTC.
The researchers found that advertisements for the OTC versions of the drugs contained significantly less information about the risks of the medication, with only 11% of the ads discussing potential risks for the OTC drugs, compared with 70% of the ads used when the drug was available by prescription only.
Direct-to-consumer advertising for prescription drugs is regulated by the Food and Drug Administration and requires the inclusion of balanced information about the risks and benefits associated with the drug. When a prescription drug switches to OTC status, regulatory oversight of consumer advertising transitions to the Federal Trade Commission, which holds drug advertisements to the same standards of truthfulness and non-deception as any other consumer product.
"This study provides some interesting insights into how drug information is presented to consumers based on the medication’s prescription or over-the-counter status," stated Troyen Brennan, EVP and chief medical officer of CVS Caremark. "Ads for prescription drugs that become available over-the-counter probably should carry the same level of information regarding the medication’s risks, benefits and side effect profile as consumers continue to need this information in order to make appropriate and informed treatment decisions."
Researchers from Harvard University, Brigham and Women’s Hospital and CVS Caremark, analyzed all print and broadcast ads for four commonly used prescription drugs (loratadine, omeprazole, orlistat and cetirizine) that were the subject of extensive direct-to-consumer promotion before and after the shift to OTC availability. The team reviewed ads spanning 24 months prior and six months following OTC shift for each drug. A total of 133 ads were reviewed for descriptive characteristics, presentation of health benefits (specific indications and claims of general health improvement) and potential health harms (side effects, contraindications, warnings and precautions).
This study is a product of a research collaboration between CVS Caremark, Harvard and Brigham and Women’s Hospital that is focused on understanding why many consumers do not take their prescriptions as directed, and developing solutions to assist patients in using their medications effectively. Excess healthcare costs due to medication nonadherence in the U.S. are estimated to be as much as $300 billion annually.